Patents by Inventor William Leonard Mitchell

William Leonard Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
    Patent number: 10442782
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: October 15, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Leonard Mitchell, Peter Johnson, Naomi Went
  • KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20180222838
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Application
    Filed: November 14, 2017
    Publication date: August 9, 2018
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Leonard Mitchell, Peter Johnson, Naomi Went
  • Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
    Patent number: 9822058
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 21, 2017
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Leonard Mitchell, Peter Johnson, Naomi Went
  • KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20150057238
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Leonard Mitchell, Peter Johnson, Naomi Went
  • Pyrimidine Derivatives And Their Use As CB2 Modulators
    Publication number: 20100041654
    Abstract: This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Application
    Filed: October 21, 2009
    Publication date: February 18, 2010
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Richard Howard Green, Jennifer Margaret Doughty, William Leonard Mitchell, Alan Naylor, Derek Anthony Rawlings, Brian Peter Slingsby, Andrew Richard Whittington
  • Pyrimidine derivatives and their use as CB2 modulators
    Patent number: 7635701
    Abstract: The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: December 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Richard Howard Green, Jennifer Margaret Doughty, legal representative, William Leonard Mitchell, Alan Naylor, Derek Anthony Rawlings, Brian Peter Slingsby, Andrew Richard Whittington
  • 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders
    Publication number: 20090264452
    Abstract: The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
    Type: Application
    Filed: February 1, 2005
    Publication date: October 22, 2009
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, William Leonard Mitchell, Alan Naylor, Derek Anthony Rawlings, Ian David Wall
  • Pyrrolopyridine derivatives
    Patent number: 7589206
    Abstract: The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: September 15, 2009
    Assignee: Glaxo Group Limited
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Matthew Russell Johnson, William Leonard Mitchell, Brian Peter Slingsby, Alcide Perboni
  • Compounds
    Publication number: 20090018128
    Abstract: The present invention relates to novel pyrrolopyrazine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Application
    Filed: January 30, 2007
    Publication date: January 15, 2009
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, William Leonard Mitchell
  • Pyridine Derivatives and Their Use as Cb2 Receptor Modulators
    Publication number: 20080280868
    Abstract: The present invention relates to novel pyridine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
    Type: Application
    Filed: February 22, 2005
    Publication date: November 13, 2008
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, William Leonard Mitchell, Alan Naylor
  • Pyridine Derivatives as Connabinoid Receptor Modulators
    Publication number: 20080280952
    Abstract: The present invention relates to novel pyridine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
    Type: Application
    Filed: February 1, 2005
    Publication date: November 13, 2008
    Inventors: Gerard Martin Paul Giblin, Karamjit Singh Jandu, William Leonard Mitchell, Ian David Wall
  • Pyrimidine Derivatives as Cannabinoid Receptor Modulators
    Publication number: 20080261977
    Abstract: The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I) and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
    Type: Application
    Filed: February 21, 2005
    Publication date: October 23, 2008
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, William Leonard Mitchell, Alan Naylor
  • Imidazopyridine Derivatives as Cannabinoid Receptor Ligands
    Publication number: 20080221097
    Abstract: The present invention relates to novel imidazopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Application
    Filed: August 7, 2006
    Publication date: September 11, 2008
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, William Leonard Mitchell, Alan Naylor, Lee William Page, Martin Swarbrick, Jennifer Anne Sweeting
  • Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine
    Publication number: 20080132505
    Abstract: Combination of one or more CB2 modulators and one or more PDE4 inhibitors, and method of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4.
    Type: Application
    Filed: February 1, 2005
    Publication date: June 5, 2008
    Inventors: Andrew James Brown, Helen Elizabeht Connor, Andrew John Eatherton, Gerard Martin Paul Giblin, Richard Howard Green, Jennifer Margaret Doughty, Karamjit Singh Jandu, Richard Graham Knowles, William Leonard Mitchell, Alan Naylor, Celestine Theresa O'Shaughnessy, Giovanni Palombi, Derek Anthony Rawlings, Brian Peter Slingsby, Catherine Jane Tralau-Stewart, Andrew Richard Whittington, Richard Alexander Williamson
  • Piperidineacetic acid derivatives useful as fibrinogen antagonist agent
    Patent number: 5861414
    Abstract: The invention provides the compounds of formula (I) ##STR1## and pharmaceutically acceptable derivatives thereof, in which: X represents either CH.sub.2 --CH.sub.2 or CH.dbd.CH, andY represents a hydrogen atom or a phenylmethyl group, wherein the phenyl group is optionally substituted by one or more halogen atoms.Compounds of formula (I) inhibit blood platelet aggregation.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: January 19, 1999
    Assignee: Glaxo Group Limited
    Inventors: David George Allen, Colin David Eldred, William Leonard Mitchell